Why Cencora (COR) is a Top Growth Stock for the Long-Term

Cencora (COR), a leading global pharmaceutical distributor, presents a compelling growth profile despite its Zacks Rank #3 (Hold). The company holds an 'A' Growth Style Score and 'A' VGM Score, supported by a projected 15.7% year-over-year earnings growth for the current fiscal year. Furthermore, six analysts have recently raised their fiscal 2025 earnings estimates to $15.92 per share, reflecting positive sentiment and the company's consistent +6.2% average earnings surprise.

Analysis

Cencora (COR) presents a compelling growth-oriented investment profile, although it is tempered by a neutral Zacks Rank #3 (Hold). As a major pharmaceutical distributor, the company demonstrates strong underlying fundamentals highlighted by its top-tier 'A' ratings for both its Growth Style Score and its overall VGM Score. The positive outlook is substantiated by a projected 15.7% year-over-year earnings growth for the current fiscal year. This forward-looking optimism is further reinforced by recent analyst activity for fiscal 2025, where six analysts revised their earnings estimates upward within the last 60 days, pushing the Zacks Consensus Estimate up by $0.11 to $15.92 per share. The company's operational execution is also notable, with a consistent history of outperformance demonstrated by an average positive earnings surprise of 6.2%. These factors collectively suggest that while the stock currently holds a neutral rating, its fundamental growth trajectory and positive earnings revisions are significant tailwinds.

Key Decisions for Investors

• Investors with a growth-focused mandate should consider Cencora for their watchlist, as its 'A' Growth Score and 15.7% forecasted earnings growth signal strong fundamental momentum.
• Monitor for any change in the Zacks Rank, as continued positive earnings estimate revisions for fiscal 2025 could be a catalyst for an upgrade from its current #3 (Hold) status.
• It is prudent to weigh the strong growth indicators and consistent earnings beats against the neutral 'Hold' rating, which may suggest that near-term price momentum or valuation concerns are currently balancing the positive long-term outlook.